Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies999
Bantam Pharmaceutical
Bantam Pharmaceutical is a drug discovery company focused on developing therapeutics for cancer patients.
Sector
Subsector
Location
total rounds
total raised
MEI Pharma
MEI Pharma is a San Diego-based pharmaceutical company developing and commercializing novel cancer therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Redx Pharma
Redx Pharma is a UK-based biotechnology company focused on developing precision medicines for oncology and fibrotic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds9
Number of Funding Rounds
Money Raised
Their latest funding was raised on 11.03.2024. Their latest investor CDTI Innovación's INNVIERTE program. Their latest round Venture - Series Unknown
SciClone Pharmaceuticals
SciClone Pharmaceuticals is a global specialty pharmaceutical company that focuses on therapies for cancer and infectious diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Co-Investors
Investors11
Number of lead investors
Number of investors
CDTI Innovación's INNVIERTE program
CDTI Innovación's INNVIERTE program
count Of Investments
EUROPEAN INNOVATION COUNCIL
The EIC Fund is the venture investment arm of the European Innovation Council (EIC). With a budget of 10 billion EUR, it supports start-ups through patient capital to minimize the risk for private investors.
count Of Investments
Svetoslava Georgieva
CTI Life Sciences Fund
CTI Life Sciences Fund is a venture capital firm based in Montreal, Canada, that focuses on investing in pharmaceutical development.
Sector
Subsector
Location
count Of Investments
count Of Exists
Shermaine Tilley
Dr. Tilley is a Partner at CTI Life Sciences Fund, L.P. Prior to joining CTI, Dr. Tilley was a Senior Vice President at Drug Royalty Corporation, a Bay Street private equity firm focused on biopharmaceutical investment. While at DRC she managed the due diligence and analysis group, and participated in transactions totaling over $200M. Before DRC, Dr. Tilley held faculty and research positions at the NYU School of Medicine and the Public Health Research Institute (PHRI), New York, and served on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health Small Business Innovation Research (SBIR) program.
current job
People
Founders2
Jordi Espadaler
Jordi obtained a BSc/MSc degree in biochemistry from the Autonomous University of Barcelona and also a PhD degree (Doctorate Extraordinary Award) from the same University. During his doctorate, Dr. Espadaler collaborated actively with Prof. Andrej Săli, a world-recognized expert in structural biology, and did several stays in his laboratory, both at the Rockefeller University (New York) and the University of California San Francisco. In 2006 he joined AB-Biotics SA when the company had just two employees and helped it to grow from a small start-up to a publicly traded company with around 40 employees.Jordi has published 10 articles in peer-reviewed journals and 3 patents (two of them are international patents), and is also a visiting professor since 2008 at the Master of Bioengineering of the Institut Químic de Sarrià (Ramon Llull University, Barcelona).In 2009 Jordi cofounded Ability Pharmaceuticals, SL to become its Vice-President, Drug Discovery in September 2009.
current job
organization founded
Jordi Espadaler
Carles Domènech
Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992).Carles has 15 years international experience in business development and licensing in the pharmaceutical industry. He held senior positions at the Barcelona pharmaceutical companies Almirall, SA (1992-2003, Manager and Head, Business Development and Licensing) and Lacer, SA (2005-2007, Director, Business Development and Licensing). Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009.
current job
organization founded
Carles Domènech
Employee Profiles6
Carles Domènech
Executive Chairman and Chief Scientific Officer
